Nilotinib (Tasigna) in the Treatment of Systemic Sclerosis. This Phase II Open Label study is currently recruiting participants. The purpose of this study is to learn how safe and tolerable a medication called Nilotinib (Tasigna) will be for patients diagnosed with Systemic Sclerosis. The secondary goal is to assess how effective Nilotinib is in treating patients with scleroderma. ClinicalTrials.gov. (Also see: Scleroderma Clinical Trials: Current Studies)
This item was posted in theISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
Nilotinib (Tasigna) in the Treatment of Systemic Sclerosis
No replies to this topic